Charlotte C. Kopitz

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression.

Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression.

Journal: Neuro-oncology advances

Published: August 21, 2024

Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12.

Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12.

Journal: ACS medicinal chemistry letters

Published: July 09, 2024

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

Journal: Cell chemical biology

Published: September 18, 2023

A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types.

A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types.

Journal: Cancers

Published: November 02, 2021

Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Journal: The Journal of biological chemistry

Published: November 28, 2020

Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Journal: The Journal of biological chemistry

Published: September 20, 2019

Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.

Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.

Journal: ACS medicinal chemistry letters

Published: August 05, 2019

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Journal: International journal of cancer

Published: September 07, 2018

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Journal: Molecular cancer therapeutics

Published: December 18, 2017

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity.

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity.

Journal: Nature

Published: December 08, 2017

Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.

Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.

Journal: Cell death & disease

Published: October 24, 2016

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.

Journal: Molecular cancer therapeutics

Published: July 20, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026